Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA opens Cleveland BioLabs' IND for CBLB-502

Oct. 20, 2011

Viralytics begins enrollment in phase II Cavatak trial following approval for dosing

Oct. 20, 2011

New protein kinase inhibitors presented by GSK

Oct. 20, 2011

Phase II study assessed combination therapy containing rilotumumab in cancer

Oct. 20, 2011

Vandetanib/bicalutamide combination trial does not meet primary endpoint

Oct. 20, 2011

BeiGene in-licenses two clinical-stage oncology candidates

Oct. 20, 2011

New carbazole-linked hybrid antitumor agents prepared

Oct. 20, 2011

Lilly begins phase II study of LY-2510924 in SCLC

Oct. 20, 2011

CSIR presents new antitumor agents

Oct. 19, 2011

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Oct. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...